EyePoint Pharmaceuticals

#BreakingNews: We are excited to announce positive interim 16-week data from our ongoing Phase 2 #VERONA clinical trial evaluating our investigational sustained delivery therapy for #DME. This prevalent disease has a significant need for more durable treatments.    Thank you to the trial investigators, patients and our internal team for your efforts as we work to develop innovative therapeutics to improve the lives of patients with serious #RetinalDiseases.    Read the press release: https://lnkd.in/eqDZX2Fu   #InvestorNews 

Today #EYPT celebrates the expansion of our presence in Massachusetts with a #RibbonCutting ceremony at our new #Northbridge location! This 40,000 sq. ft. cGMP facility will accelerate clinical development and future commercial production for our lead #Pipeline candidate in #WetAMD and #DME.     With state-of-the-art facilities and a dedicated team, we are poised to deliver innovative therapeutics to patients living with serious #RetinalDiseases. Thank you to everyone who contributed to this milestone!    #InvestorNews #RetinaNews #BostonNews #BioTech 

#EYPT announces pricing of upsized public offering. Read the press release: https://lnkd.in/edtVixwN

Thank you to our Phase 3 #LUGANO trial lead investigator, Ashkan Abbey, MD, for your leadership and expertise as we further the advancement of therapies for patients living with serious #RetinalDiseases.     Analyzing learnings from our robust #DAVIO and #DAVIO2 trials, #LUGANO was designed following a proven non-inferiority approval pathway for potential global #regulatory and #commercial success.    Encouraged by enthusiasm from both patients and investigators in our earlier-stage trials, we look forward to continued patient enrollment in this global trial.    Learn more: https://lnkd.in/eMQNVsa     #RetinaPipeline #InvestorNews  

#ICYMI: #EYPT announced positive interim 16-week data for the ongoing Phase 2 #VERONA trial evaluating our investigational sustained delivery therapy in #DME.    Thank you to all involved in this clinical trial, including the site investigators, our internal team, and most importantly, patients. We look forward to sharing full topline data in Q1 2025 as we deliver on our commitment to improving the lives of patients living with serious #RetinalDiseases.      Read the full data results: https://lnkd.in/eqDZX2Fu     #InvestorNews 

Adam Gerstenblith, M.D., a #VERONA principal investigator and vitreoretinal surgeon at Mid Atlantic Retina Specialists, shares more about the current treatment burden faced by patients with #DME.     Read the press release: https://lnkd.in/eqDZX2Fu  

#WetAMD can cause irreversible vision loss, and patients currently face a high treatment burden.     #LUGANO principal investigator, Ashkan Abbey, MD shares more about the exciting progress for our global Phase 3 LUGANO #WetAMD clinical trial, which looks to potentially reduce this burden and revolutionize real-world outcomes for patients.    #InvestorNews #RetinaPipeline

#EYPT President & CEO Jay S. Duker, M.D. expands on how the intentional Ph3 #LUGANO and #LUCIA #WetAMD trial designs leverage learnings from our robust #DAVIO and #DAVIO2 trials to potentially revolutionize real-world outcomes for patients.    With over 150 sites already committed, we look forward to continued enrollment as we work to change the treatment paradigm for patients living with serious #RetinalDiseases.    Learn more about our Phase 3 Program here: https://lnkd.in/ecbAUaQR  

#BreakingNews: We are excited to announce that the first patient has been dosed in our global Phase 3 #LUGANO clinical trial evaluating our investigational sustained delivery therapy for #wetAMD.    Thank you to the trial investigators, patients and our internal team for your efforts to achieve this milestone as we work to develop innovative therapeutics to improve the lives of patients with serious #RetinalDiseases.    With over 150 sites already committed, we look forward to continued enrollment, with topline data anticipated in 2026.  Read the press release: https://lnkd.in/ecbAUaQR #InvestorNews

Thank you to the American Academy of Ophthalmology for a great #AAO2024! We enjoyed connecting with other #Ophthalmology leaders and discussing the latest innovations in #RetinalDisease. Check out some of our favorite moments while in Chicago.